BioCentury | Feb 22, 2018
Product R&D

Shooting for the universe

...it to the clinic but been discontinued, including a recombinant fusion protein from now defunct VaxInnate Corp....
BioCentury | Jun 22, 2015
Clinical News

VAX2012Q: Phase II started

...Euronext:SAN; NYSE:SNY, Paris, France) in up to 450 healthy adults. The trial is funded by VaxInnate’s...
...Advanced Research and Development Authority (BARDA) (see BioCentury, March 7, 2011 & March 9, 2015). VaxInnate Corp....
BioCentury | May 14, 2015
Company News

Management tracks

...chief information officer from VP of pharmaceutical operations and corporate information technology. Infectious disease company VaxInnate Corp....
BioCentury | Mar 19, 2015
Distillery Therapeutics

Therapeutics: Influenza A virus hemagglutinin

...binds a conserved region on hemagglutinin, in Phase II testing to treat influenza A virus. VaxInnate Corp....
BioCentury | Mar 9, 2015
Company News

VaxInnate, U.S. Department of Health and Human Services infectious news

...The contract extension will provide the remaining $53 million in funding through February 2016. VaxInnate...
...2Q15; a Phase I and Phase II trial of VAX161C; and to prepare commercial formulations. VaxInnate...
...a recombinant influenza vaccine that combines influenza and bacteria proteins (see BioCentury, March 7, 2011). VaxInnate Corp....
BioCentury | Jan 5, 2015
Clinical News

VAX2012Q: Phase Ib/II started

...12, 20, 28 or 36 µg VAX2012Q in up to 200 healthy volunteers ages 65-75. VaxInnate Corp....
BioCentury | Nov 24, 2014
Clinical News

VAX2012Q: Phase I data

...tolerated with mild to moderate arm pain reported as the most common adverse event. Additionally, VaxInnate...
...mean seroprotection rates of >90% for each of the 4 vaccine components at day 21. VaxInnate Corp....
BioCentury | Nov 13, 2014
Cover Story

Boosting adjuvants

...Inc. (NASDAQ:NVAX); Johnson & Johnson (NYSE:JNJ) Phase I/II Flagellin TLR5 ligand VAX102, an influenza vaccine VaxInnate Corp....
BioCentury | Oct 20, 2014
Product Development

Walking the toll road

...Lead indication Status Immune Design Corp. (NASDAQ:IMDZ) G100 TLR4 Merkel cell carcinoma (MCC) Ph I VaxInnate Corp....
...BioLabs Inc. (NASDAQ:CLBI) Entolimod (CBLB502) TLR5 Acute radiation syndrome (ARS); solid tumors Ph I (A) VaxInnate Corp....
BioCentury | Mar 24, 2014
Clinical News

VAX2012Q: Phase I started

...intramuscular VAX2012Q in up to 320 healthy volunteers ages 18-40. The trial is funded by VaxInnate's...
...a recombinant influenza vaccine that combines influenza and bacteria proteins (see BioCentury, March 7, 2011). VaxInnate Corp....
Items per page:
1 - 10 of 66
BioCentury | Feb 22, 2018
Product R&D

Shooting for the universe

...it to the clinic but been discontinued, including a recombinant fusion protein from now defunct VaxInnate Corp....
BioCentury | Jun 22, 2015
Clinical News

VAX2012Q: Phase II started

...Euronext:SAN; NYSE:SNY, Paris, France) in up to 450 healthy adults. The trial is funded by VaxInnate’s...
...Advanced Research and Development Authority (BARDA) (see BioCentury, March 7, 2011 & March 9, 2015). VaxInnate Corp....
BioCentury | May 14, 2015
Company News

Management tracks

...chief information officer from VP of pharmaceutical operations and corporate information technology. Infectious disease company VaxInnate Corp....
BioCentury | Mar 19, 2015
Distillery Therapeutics

Therapeutics: Influenza A virus hemagglutinin

...binds a conserved region on hemagglutinin, in Phase II testing to treat influenza A virus. VaxInnate Corp....
BioCentury | Mar 9, 2015
Company News

VaxInnate, U.S. Department of Health and Human Services infectious news

...The contract extension will provide the remaining $53 million in funding through February 2016. VaxInnate...
...2Q15; a Phase I and Phase II trial of VAX161C; and to prepare commercial formulations. VaxInnate...
...a recombinant influenza vaccine that combines influenza and bacteria proteins (see BioCentury, March 7, 2011). VaxInnate Corp....
BioCentury | Jan 5, 2015
Clinical News

VAX2012Q: Phase Ib/II started

...12, 20, 28 or 36 µg VAX2012Q in up to 200 healthy volunteers ages 65-75. VaxInnate Corp....
BioCentury | Nov 24, 2014
Clinical News

VAX2012Q: Phase I data

...tolerated with mild to moderate arm pain reported as the most common adverse event. Additionally, VaxInnate...
...mean seroprotection rates of >90% for each of the 4 vaccine components at day 21. VaxInnate Corp....
BioCentury | Nov 13, 2014
Cover Story

Boosting adjuvants

...Inc. (NASDAQ:NVAX); Johnson & Johnson (NYSE:JNJ) Phase I/II Flagellin TLR5 ligand VAX102, an influenza vaccine VaxInnate Corp....
BioCentury | Oct 20, 2014
Product Development

Walking the toll road

...Lead indication Status Immune Design Corp. (NASDAQ:IMDZ) G100 TLR4 Merkel cell carcinoma (MCC) Ph I VaxInnate Corp....
...BioLabs Inc. (NASDAQ:CLBI) Entolimod (CBLB502) TLR5 Acute radiation syndrome (ARS); solid tumors Ph I (A) VaxInnate Corp....
BioCentury | Mar 24, 2014
Clinical News

VAX2012Q: Phase I started

...intramuscular VAX2012Q in up to 320 healthy volunteers ages 18-40. The trial is funded by VaxInnate's...
...a recombinant influenza vaccine that combines influenza and bacteria proteins (see BioCentury, March 7, 2011). VaxInnate Corp....
Items per page:
1 - 10 of 66